Pubertal high fat diet: effects on mammary cancer development by Zhao, Yong et al.
Zhao et al. Breast Cancer Research 2013, 15:R100
http://breast-cancer-research.com/content/15/5/R100RESEARCH ARTICLE Open AccessPubertal high fat diet: effects on mammary
cancer development
Yong Zhao1, Ying Siow Tan1, Mark D Aupperlee1, Ingeborg M Langohr3, Erin L Kirk4, Melissa A Troester4,5,
Richard C Schwartz2* and Sandra Z Haslam1,6*Abstract
Introduction: Epidemiological studies linking dietary fat intake and obesity to breast cancer risk have produced
inconsistent results. This may be due to the difficulty of dissociating fat intake from obesity, and/or the lack of
defined periods of exposure in these studies. The pubertal mammary gland is highly sensitive to cancer-causing
agents. We assessed how high fat diet (HFD) affects inflammation, proliferative, and developmental events in the
pubertal gland, since dysregulation of these can promote mammary tumorigenesis. To test the effect of HFD initi-
ated during puberty on tumorigenesis, we utilized BALB/c mice, for which HFD neither induces obesity nor meta-
bolic syndrome, allowing dissociation of HFD effects from other conditions associated with HFD.
Methods: Pubertal BALB/c mice were fed a low fat diet (12% kcal fat) or a HFD (60% kcal fat), and subjected to
carcinogen 7,12-dimethylbenz[a]anthracene (DMBA)-induced tumorigenesis.
Results: HFD elevated mammary gland expression of inflammatory and growth factor genes at 3 and 4 weeks of
diet. Receptor activator of nuclear factor kappa-B ligand (RANKL), robustly induced at 4 weeks, has direct mitogenic
activity in mammary epithelial cells and, as a potent inducer of NF-κB activity, may induce inflammatory genes.
Three weeks of HFD induced a transient influx of eosinophils into the mammary gland, consistent with elevated
inflammatory factors. At 10 weeks, prior to the appearance of palpable tumors, there were increased numbers of
abnormal mammary epithelial lesions, enhanced cellular proliferation, increased growth factors, chemokines associated
with immune-suppressive regulatory T cells, increased vascularization, and elevated M2 macrophages. HFD dramatically
reduced tumor latency. Early developing tumors were more proliferative and were associated with increased levels of
tumor-related growth factors, including increased plasma levels of HGF in tumor-bearing animals. Early HFD tumors
also had increased vascularization, and more intra-tumor and stromal M2 macrophages.
Conclusions: Taken together in this non-obesogenic context, HFD promotion of inflammatory processes, as well as
local and systemically increased growth factor expression, are likely responsible for the enhanced tumorigenesis. It is
noteworthy that although DMBA mutagenesis is virtually random in its targeting of genes in tumorigenesis, the
short latency tumors arising in animals on HFD showed a unique gene expression profile, highlighting the potent
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Eradication of breast cancer will be significantly advanced
by the development of effective prevention strategies.
Dietary fat intake and increased body mass index (BMI)/
obesity have been studied for their potential contributions
to breast cancer risk. High BMI (BMI ≥25 kg/m2) is a rec-
ognized risk factor for postmenopausal breast cancer in
the pooled analysis of data from large, prospective cohort
studies [1]. Conversely, in the same analysis, high BMI
(BMI >31) is associated with reduced risk for premeno-
pausal breast cancer [1]. Similarly, weight gain in adult
years is associated with increased risk for postmenopausal
breast cancer and reduced risk for premenopausal breast
cancer [2]. The relationship between dietary factors, spe-
cifically dietary fat, the major contributor to increased
BMI, and breast cancer risk is less clear. Recent research
has demonstrated no associations with breast cancer risk
for adult intake of total fat, saturated fat, or other specific
types of dietary fat. These findings did not vary by ethni-
city, estrogen/progesterone receptor status, tumor stage,
BMI, hormone replacement therapy use, follow-up period,
family history of breast cancer, or smoking status at base-
line [3]. Lack of associations between dietary factors and
breast cancer risk could be the result of numerous sources
of bias, including misclassification of dietary intake.
Furthermore, the time period in which diet may play
the most important role is unclear. In this regard, diet-
ary data usually reflect diet for the year prior to diagno-
sis or in adulthood prior to breast cancer. Thus, there
is a need for a better understanding of the relative con-
tributions of diet, and the timing of diet and/or obesity,
to breast cancer risk.
Based on studies in humans and rodents, there is now
wide recognition that the origins of breast cancer prob-
ably occur early in development, especially during the
times of rapid breast development in the pubertal transi-
tion [4]. Emerging evidence indicates that the compos-
ition, cellular proliferation, and maturation of the gland
can be altered by diet and environmental exposures, and
that exposure during puberty is particularly relevant [5].
An important gap in our understanding is how diet and/
or increased BMI specifically influence pubertal breast
development and breast cancer risk in adulthood. The
typical western diet, high in saturated fat, is largely cred-
ited for the obesity epidemic in the US. However, it
should be noted that there are more people who eat a
high-fat western diet and potentially suffer its conse-
quences, than are actually obese. At the same time, the
effects of diet versus those of increased BMI are difficult
to distinguish, since a high fat diet (HFD) often results
in increased BMI.
Among the mechanisms proposed for diet/obesity-
associated breast cancer risk are altered glucose metab-
olism, altered steroid hormone levels, and inflammatoryprocesses [6]. It is entirely possible that HFD during
puberty may alter breast development, independent-
ly of increasing BMI, through one or more of these
mechanisms, thereby modifying the risk for breast
cancer.
Ovarian hormones and growth factors are primary
factors driving pubertal mammary gland development
in humans and rodents. Estrogen (E) and progesterone
(P) promote epithelial cell proliferation by inducing
amphiregulin (Areg), a growth factor produced in estro-
gen receptor α (ERα)- and progesterone receptor (PR)-
positive cells, that acts through a paracrine mechanism
in the stroma and in ER negative mammary epithelial
cells [7,8].
Macrophages and eosinophils play important roles in
normal pubertal mammary gland development in the
mouse [9] and, in the case of macrophages, also contrib-
ute to mammary tumor progression [10]. Macrophage
association with terminal end buds is needed for ductal
elongation and eosinophils are required for proper
ductal development, particularly branching. Mast cells
have also been implicated in pubertal mammary gland
ductal morphogenesis, with a role independent of that of
macrophages [11]. Importantly, inflammatory leukocytes
are involved in several animal models of mammary tumor
progression [12,13]. A diet high in saturated fat, that may
increase inflammatory processes in the mammary gland,
may also promote mammary tumorigenesis [14-17].
We previously investigated the impact of HFD on pu-
bertal mammary gland development in BALB/c mice
[18]. Pubertal mice were fed non-isocaloric diets that
were either high in saturated fat (HFD, 60% kcal from
fat) or low in saturated fat (LFD, 12% kcal from fat) dur-
ing the peri-pubertal period from 3 to 7 weeks of age.
Notably, HFD significantly increased mammary epithe-
lial cell proliferation without a significant increase in
body weight [18]. That study showed a small increase in
fasting blood glucose and plasma insulin levels, and no
difference in plasma E levels after 4 weeks on the diets.
The purpose of the present study was to investigate the
effects of HFD initiated in the peri-pubertal period on
mammary gland susceptibility to DMBA-induced mam-
mary tumorigenesis in adulthood in a non-obesogenic
context in BALB/c mice. We sought to examine the po-
tential effects on proliferation, inflammatory processes,
glucose metabolism and altered hormone levels in the
context of mammary tumorigenesis.
The results obtained showed a significant decrease in
tumor latency in HFD-fed mice. The association of
HFD-induced decreased latency with local and systemic-
ally increased growth factor expression, and promotion
of inflammatory and angiogenic processes, suggest likely
mechanisms for enhanced tumorigenicity. Importantly,
these HFD-induced effects occurred without significant
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and insulin levels, or E and P levels. Furthermore, tu-
mors occurring with reduced latency on HFD displayed
a gene expression profile that clearly distinguished them
from tumors occurring on LFD.
Materials and methods
Animals
Three-week-old female BALB/c mice were obtained
from Charles River Laboratories (Portage, MI, USA).
Mothers of these mice were maintained on LabDiet
5 L79 (PMI Nutrition International LLC, St. Louis, MO,
USA) before and during pregnancy, and while nursing.
Upon arrival, mice were randomly distributed into two
non-isocaloric diet groups, LFD or HFD. Animals were
housed in polysulfone cages, and received measured
amounts of food and water ad libitum. Housing facilities
were maintained on a 12:12 h light–dark cycle, at 20 to
24°C with 40 to 50% relative humidity. All animal ex-
perimentation was conducted in accord with accepted
standards of humane animal care and approved by the
All University Committee on Animal Use and Care at
Michigan State University.
Diets
Diets were initiated at 3 weeks of age and maintained
throughout the experimental period up to 45 weeks of
age. Two diets (I and II) were used in these studies. Diet
I: low fat diet 58G7 (12% kcal fat - LFD) and high fat
diet 58G9 (60% kcal fat - HFD) were purchased from
TestDiet (PMI Nutrition International LLC). Initial con-
cern over the carbohydrate content of Diet I and the po-
tential for the development of metabolic syndrome led
us to also use Diet II, which contained maltodextrin in-
stead of the dextrin and sucrose contained in Diet I. Diet
II: low fat diet 12450B (10% kcal fat - LFD) and high fat
diet 12492 (60% kcal fat - HFD), both with corn oil re-
placing soy oil, were purchased from Research Diets
(New Brunswick, NJ, USA). For Diet I, 11% kcal fat
came from corn oil, with the remainder of the fat (1 or
49% kcal) coming from lard. For Diet II, 5.5% kcal fat
came from corn oil, with the remainder of the fat (4.5 or
54.5% kcal) coming from lard. Detailed composition of
Diets I and II is described in Additional file 1. LFD and
HFD Diets I and II did not differ significantly with regard
to their effects on body weight, blood glucose, insulin
levels, tumor incidence, or tumor latencies (see Additional
files 2, 3, 4, 5). Therefore, results obtained on tumorigen-
esis with the two diets were combined.
Tumorigenesis
Mice were treated with 7,12-dimethylbenz(a)anthracene
(DMBA) (Sigma-Aldrich, St. Louis, MO, USA) prepared in
vegetable oil and administered by oral gavage (50 mg/kgbody weight/mouse) once per week for 4 weeks starting
at 5 weeks of age. Body weights were monitored weekly,
and animals were palpated for tumors once a week starting
at 8 weeks post first DMBA dose (see Additional file 6).
Tumor volume was measured twice per week, and har-
vested at 1 cm size. At 2 h prior to sacrifice, mice were
injected with 5-bromo-2’-deoxyuridine (BrdU) (70 μg/g
body weight; Sigma-Aldrich) for analysis of cellular prolif-
eration. At termination of all feeding studies, portions of
tumors and mammary tissues were either snap frozen for
protein and RNA isolation, or formalin fixed and either
processed as whole mounts [19] or paraffin embedded for
H&E staining and immunohistochemistry [20]. Whole-
mount preparations of glands and H&E sections were
scored for the presence of hyperplasia and neoplasia [21].
There were no notable diet effects on mammary gland
morphology as assessed by whole mounts or histological
sections at the time points analyzed. All lesions and tumors
were reviewed and classified, as previously described [22].
Metabolic parameters
Plasma glucose and insulin levels were the metabolic
parameters measured. Non-fasting, randomly sampled
glucose and insulin levels were obtained from mice fed
ad libitum, as an appropriate and acceptable method
based on mouse feeding habits and the stress caused by
fasting [23]. Plasma levels of glucose were determined
by AccuChek Compact Glucometer (Roche, Nutley, NJ,
USA) and insulin levels were determined with an insu-
lin ELISA kit from EMD Millipore (Cat. number:
EZRMI-13 K; St. Charles, MO, USA), following the
manufacturer’s instructions.
Estrogen and progesterone assay
Total serum E levels were determined using Delfia Estradiol
time-resolved fluoroimmunoassay (Cat. number: 1244–056;
PerkinElmer, Turku, Finland), following the manufacturer’s
instructions. The levels of serum P were measured by
ELISA (Cat. number: 11-PROHU-E01; Alpco Diagnos-
tics, Salem, NH, USA), following the manufacturer's
instructions.
Estrogen receptor analysis
Mammary gland or tumor sections (5 μm) were pre-
pared and subjected to antigen retrieval and immuno-
fluorescent staining, as previously described [20]. Briefly,
sections were blocked with goat anti-mouse immuno-
globulin G (IgG) Fab (antigen binding fragment; 1:100
with 1% BSA in PBS (PBSA)) for 1 h at room
temperature (RT), followed by blocking with normal
goat serum in PBS for 30 minutes at RT. Then, sections
were incubated with mouse anti-ERα (1:10 in PBS-0.5%
Triton X-100; Cat. number: NCL-ER-6 F11; Novocastra
Laboratories Ltd, Newcastle upon Tyne, UK) at 4°C
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with an Alexa 488-labeled goat anti-mouse secondary
antibody (Ab) (1:200 in PBS; Invitrogen Molecular
Probes, Grand Island, NY, USA) at RT for 30 minutes,
and then counterstained with 4’,6-diamidino-2-phenylin-
dole (DAPI) for 5 minutes. The stained sections were
visualized with a Nikon Eclipse TE2000-U fluorescence
microscope (Nikon, Inc., Melville, NY, USA) using a 40X
objective lens, and the captured fluorescent images were
analyzed using MetaMorph software (Molecular Devices,
LLC, Sunnyvale, CA, USA). A minimum of 1,000 cells
were counted for each tumor. Tumors were considered
to be ERα-positive (ER+) if 10% or more of the total cells
counted were ER + [24].
Macrophage analysis
Mammary gland or tumor sections (5 μm) were pre-
pared for immunofluorescent staining [20]. Briefly, after
deparaffinization, mammary gland sections were sub-
jected to antigen retrieval at 121°C and 15 pounds per
square inch (psi) for 5 minutes; tumor sections did not
receive antigen retrieval, as the integrity of tumor sec-
tions was compromised by the procedure, and staining
was adequate in its absence. All sections were treated
with proteinase K (20 μg/mL in Tris-EDTA buffer,
pH 8.0) at 37°C for 3.5 minutes. After brief washes with
PBS, sections were blocked with normal rabbit serum in
PBS, followed by incubation with goat anti-Arginase 1
(Arg1) (1:200 in PBS-0.5% Triton X-100; Cat. number:
sc-18354; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) at 4°C overnight. After brief washes, sections
were incubated with Alexa 546-labeled rabbit anti-goat
secondary Ab (1:100 in PBS; Cat. number: A21085; Invi-
trogen Molecular Probes) at RT for 30 minutes and then
blocked with normal goat serum in PBS for 30 minutes.
The sections were then incubated with rat monoclonal
anti-F4/80 (1:75 in PBS-0.5% Triton X-100; Cat. number:
MCA497R; AbD Serotec, Raleigh, NC, USA) at 4°C
overnight, followed by incubation with Alexa 488-
labeled goat anti-rat secondary Ab (1:100 in PBS; Invi-
trogen Molecular Probes) at RT for 30 minutes and
counterstaining with DAPI for 5 minutes. The stained
sections were visualized with a Nikon Eclipse TE2000-U
fluorescence microscope (Nikon, Inc.) using a 40X ob-
jective lens, and the captured fluorescent images were
analyzed using MetaMorph software (Molecular Devices,
LLC). The number of F4/80 and/or Arg1-positive cells is
expressed as cells per structure in the mammary gland
peri-epithelial area, and cells per image in tumor
samples.
Cellular proliferation analysis
Mammary gland or tumor sections (5 μm) were prepared
and immunoperoxidase staining was performed [20].Briefly, after deparaffinization, sections were incubated
in 3% of hydrogen peroxide (H2O2) in methanol for
10 minutes. Then sections were subjected to antigen re-
trieval at 121°C and 15 psi for 15 minutes. Sections
were blocked with goat anti-mouse IgG Fab (1:100 in
1% PBSA) for 1 h, followed by blocking with normal
goat serum in PBS. Then, sections were incubated with
mouse anti-BrdU (1:100 in PBS-0.5% Triton X-100; Cat.
number: ab27958; Abcam plc, Cambridge, MA, USA) at
4°C overnight. After a brief wash, sections were incubated
with goat anti-mouse biotin secondary Ab (1:400 in PBS;
DAKO Denmark A/S, Glostrup, Denmark) at RT for
30 minutes, and then incubated with ABC reagent (PK-
7100, Vector laboratories, Inc., Burlingame CA, USA) for
30 minutes. The sections were then incubated with metal-
enhanced 3,3-diaminobenzidine (DAB) substrate solu-
tion (100 μL of DAB substrate + 900 μL stable peroxide
substrate buffer; Thermo Scientific, Rockford, IL, USA)
for 7 minutes and counterstained with hematoxylin for
2 minutes. The stained sections were visualized with a
Nikon Eclipse E400 light microscope (Nikon, Inc.)
using a 40X objective lens. A minimum of 1,000 cells
were counted for each section, and a minimum of two
to three tissue sections per animal were analyzed. The
number of BrdU-positive cells is expressed as the per-
centage of total epithelial cells counted.Immunohistochemical analysis of blood vessel density
Mammary gland or tumor sections (5 μm) were depar-
affinized and were incubated in 2% H2O2 in methanol/
PBS (1:1 ratio) for 30 minutes followed by antigen re-
trieval by boiling at 95°C for 5 minutes. Sections were
then treated for 2 h with rabbit anti-CD31 (1:50 in
PBS-0.5% Triton X-100; Cat. number: AP15436PU-N;
Acris Antibodies, Inc., San Diego, CA, USA) for endo-
thelial cell staining and detection of blood vessels.
After a brief wash, sections were incubated with sec-
ondary swine anti-rabbit Ab at RT for 30 minutes, and
then incubated with ABC reagent (PK-7100, Vector la-
boratories, Inc.) for 30 minutes. The sections were
then incubated with metal-enhanced DAB substrate
solution (100 μL of DAB substrate + 900 μL stable per-
oxide substrate buffer; Thermo Scientific) for 7 minutes
and counterstained with hematoxylin for 2 minutes.
The stained sections were visualized with a Nikon
Eclipse E400 light microscope (Nikon, Inc.) using a
40X objective lens. A minimum of 1,000 cells were
counted for each section, and a minimum of two to
three tissue sections per animal were analyzed. Digital
micrographs were captured and the images were over-
laid with grids containing 240 squares (324 μm2/
square). Blood vessel density is expressed as the per-
centage of CD31-positive squares.
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Deparaffinized 5-μm sections were stained with Astra
Blue/Vital New Red [25]. Sections dehydrated in 95%
ethanol for 5 sec were incubated in Astra Blue solution
(5 mg/mL in 75% ethanol) for 30 minutes at RT. After
rinsing in double-distilled water (H2O), sections were
again dehydrated in 95% ethanol for 5 sec, and then in-
cubated in Vital New Red solution (0.2 g/L in 50% etha-
nol) for 1 h at RT and counterstained with hematoxylin
for 2 minutes. The stained sections were visualized with
a Nikon Eclipse E400 light microscope (Nikon, Inc.)
using a 40X objective lens. The number of eosinophils
and mast cells is expressed as cells per structure in the
mammary gland peri-epithelial area.
Mammary gland structure analysis
Sections stained for macrophages, cellular proliferation,
eosinophils, and mast cells were analyzed by mammary
gland epithelial structure: small ducts, large ducts, ter-
minal end buds (TEBs), or hyperplastic foci. Large ducts
were qualitatively characterized by larger lumen diam-
eter, comprising greater than 50 cells in a section, and
by an extensive extracellular matrix and fibroblasts sur-
rounding the epithelium. Conversely, small ducts were
qualitatively characterized by smaller lumen diameter,
comprising fewer than 50 cells, and by a limited extra-
cellular matrix surrounding the epithelium. TEBs were
characterized by location within the gland, presence of
multiple epithelial cell layers, and direct apposition of
epithelium to adipocytes without extracellular matrix.
Hyperplastic structures had multiple cell layers of no-
ticeably distorted epithelium compared to normal epi-
thelial structures.
Quantitative PCR arrays and quantitative reverse
transcription-PCR analysis (qRT-PCR)
Total RNA was isolated from mouse mammary glands
(intact or cleared fat pads) or tumors using TRIzol® re-
agent (Invitrogen, Carlsbad, CA, USA) and purified
using the RT2 qPCR-Grade RNA isolation kit (SABios-
ciences, Frederick, MD, USA). We used 3 μg of total
RNA for first strand cDNA synthesis using the RT2 First
Strand kit (SABiosciences), following the manufacturer’s
instructions. The cDNA (20 μL) were diluted to 150 μL
with de-ionized H2O. RNA expression was then analyzed
using targeted PCR arrays (SABiosciences) for Breast
Cancer (PAMM-131), Cancer Pathway Finder (PAMM-
033), Growth Factors (PAMM-041), and Inflammatory
Cytokines and Receptors(PAMM-011). In addition to the
arrays, primers for the following selected RNA were pur-
chased from SABiosciences: Tnfs11 (RANKL) (PPM03047E),
18S ribosomal RNA (rRNA) (PPM57735E), Ribosomal pro-
tein L32 (RPL32) (PPM03300B). For qRT-PCR analysis, each
reaction (25 μL) included 12.5 μL of 2X SABiosciences RT2qPCR Master Mix (SYBR Green), 1 μL of diluted first-
strand cDNA synthesis reaction, and 11.5 μL of de-
ionized H2O. qRT-PCR was performed with the ABI
7500 Fast Real-Time PCR System (Applied Biosystems,
Inc., Foster City, CA, USA) using the following pro-
gram: step 1: 95°C, 10 minutes; step 2: 40 cycles of 95°C,
15 s and 60°C, 1 minute; step 3: dissociation curve
95°C, 1 minute; 65°C, 2 minutes (optics off); 65 to 95°C at
2°C per minute (optics on). The data were analyzed using
online software from SABiosciences [26]. For RANKL
RNA, the comparative cycle threshold (CT) method was
used to calculate the fold change in gene expression after
normalization to the values for 18S rRNA and RPL32
RNAs. RNA from the number 4-inguinal mammary
glands of three animals was analyzed from each treatment
group. In the tumor analysis, the three HFD-E tumors
were adenosquamous (ER-), ductal (ER+) and cribriform
(ER-) adenocarcinomas with tumor onset at 10, 14 and
17 weeks post-DMBA, respectively. The three LFD tu-
mors were adenosquamous (ER-), papillary (ER+) and
cribriform (ER-) adenocarcinomas with tumor onset at 31,
34 and 38 weeks post-DMBA, respectively.
Pathway analysis
Genes that were significant (unadjusted p-value <0.05) in
univariate analyses were evaluated for ontological enrich-
ment using Ingenuity Pathway Analysis (IPA, Ingenuity®
Systems, Redwood City, CA, USA), with Benjamini-
Hochberg (B-H) multiple testing correction. The back-
ground was set to include only the genes on the qPCR
arrays analyzed for each sample group. Significant func-
tions and pathways were defined as those with at least two
significant genes per pathway and with B-H P-values less
than 0.05.
Analysis of plasma cytokine levels
Plasma levels of 20 different cytokine proteins (AREG,
basic fibroblast growth factor (bFGF), epidermal growth
factor (EGF), hepatocyte growth factor (HGF), insulin-
like growth factor 2 (IGF-2), IL-6, leptin, receptor activa-
tor of nuclear factor kappa-B ligand (RANKL), vascular
endothelial growth factor (VEGF), resistin, TNFα, IL-1α,
IL-1β, insulin-like growth factor binding protein (IGFBP)-
2, IGFBP-3, prolactin, T-cell activation (TCA)-3 (CCL1),
macrophage colony stimulating factor (M-CSF), epiregu-
lin, and osteoprotegerin (OPG)) were determined by cyto-
kine Ab arrays (Cat. number: AAM-CUS-G; RayBiotech,
Norcross, GA, USA), following the manufacturer’s in-
structions. Briefly, the glass array slide was incubated with
blocking buffer for 30 minutes at RT, and then incubated
with diluted mouse plasma (30 μL plasma diluted to
120 μL with blocking buffer) overnight at 4°C with slow
shaking. Then, after thorough washing with washing buf-
fer, the array slide was incubated with biotin-labeled Ab
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with washing buffer, the array slide was incubated with
HiLytePlus™ 555 Fluor-conjugated streptavidin for 2 h at
RT with slow shaking. Then, after thorough washing, the
slide was dried and absolute fluorescent intensity mea-
sured by an Agilent G2505B laser scanner (Agilent Tech-
nologies, Inc., Santa Clara, CA, USA). The data were
analyzed by software provided by the company. Addition-
ally, plasma IGF-1 levels were measured using a mouse
IGF-1 ELISA kit (ELM-IGFI-001; RayBiotech), according
to the manufacturer’s directions.
Statistical analyses
The PCR arrays were statistically analyzed using propri-
etary software from SABiosciences. Correlations between
cytokine mRNA levels and leukocyte populations were de-
termined by Spearman’s method [27]. Otherwise, results
are expressed as mean ± standard error of the mean (SEM).
Differences were considered significant at P <0.05 using the
Student t-test or analysis of variance (ANOVA) followed by
the Tukey multiple comparison test, as appropriate. Tumor
incidence was analyzed by the Chi-square test. Tumor
latencies were determined from Kaplan-Meier plots.
Results
HFD decreases tumor latency
A Kaplan-Meier plot (Figure 1A) shows that HFD-fed
mice developed tumors significantly earlier than LFD-Figure 1 Characteristics of tumor development in high fat diet- versus
high fat diet (HFD)- and low fat diet (LFD)-fed mice. Time = number of da
mice, n = 95; LFD mice, n = 87) (B) Time-course of epithelial proliferative l
developed in HFD-fed DMBA-treated mice at 8 and 14 weeks post first D
of lesions per mouse; n = 5 mice at each time for HFD and LFD. *P = 0.05;
duct hyperplasia, (ii) lobular hyperplasia, and (iii) mixed dysplasia. Scale bfed mice (P = 0.01) with a significantly reduced median
time to tumor onset (204 days LFD versus 115 days
HFD; P = 0.00075). Although HFD caused a 1.8-fold in-
crease in tumor incidence (LFD, 14.95%, n = 87 mice
versus HFD, 26.3%, n = 95 mice; P = 0.059), this did not
reach statistical significance. Notably, there were no sig-
nificant differences in body weight (see Additional file 2)
or in parametrial fat pad weights (data not shown) be-
tween animals fed HFD and LFD over the course of the
tumor study.
Since decreased latency was the major difference be-
tween the two diets, we focused on investigating the
basis for the latency difference. To that end, we focused
our analysis on comparing early developing tumors on
HFD (HFD-E) tumors with LFD tumors. Representative
HFD-E tumors were selected from tumors that devel-
oped before the earliest observed LFD tumors, at
19 weeks or less post-first DMBA treatment. Conversely,
representative LFD tumors were selected after 19 weeks
or more post-first DMBA treatment, when LFD tumors
were first detected. We considered the possibility that
reduced latency in HFD-fed mice might be due to accel-
erated development and increased numbers of atypical
hyperplastic, pre-cancerous lesions. Time-course analysis
showed that, indeed, HFD-fed mice developed signifi-
cantly more hyperplastic lesions per mouse after 8 and
14 weeks post-first DMBA treatment (10 and 16 weeks
on diet, respectively), times before palpable tumors werelow fat diet-fed mice. (A) Kaplan-Meier plot of all tumors developing in
ys post last 7,12-dimethylbenz[a]anthracene (DMBA) treatment (HFD
esion development. More hyperplastic and precancerous lesions
MBA treatment. Bars represent mean ± standard error of the mean
**P = 0.003. (C) Epithelial proliferative lesions comprised (i) terminal
ar = 1 mm.
Table 1 Tumor histopathology
Tumor N Adenocarcinoma type ER statusa
Low fat diet 13 7/13 glandular/acinar 7/13 ER+
3/13 adenosquamous
3/13 papillary
High fat diet-early 10 3/10 glandular/acinar 6/10 ER+
7/10 adenosquamous
aEstrogen receptor (ER) status based on >10% receptor-positive cells. High fat
diet-early represents mice with early developing tumors while on the high
fat diet.
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ductal and alveolar hyperplasia for both diets (Figure 1C).
There were no significant differences in tumor types or
ER status (Table 1).
Effects of diet on mammary gland and tumor
proliferation
We examined mammary epithelial cell and tumor cell
proliferation, as determined by BrdU incorporation, at
10 weeks on diet and in tumors (Figure 2A). These mea-
surements were compared to our earlier report of HFD-
enhanced proliferation at 4 weeks on diet [18]. At both 4
and 10 weeks on diet, there were significant increases in
epithelial cell proliferation in HFD-fed mice, with theFigure 2 Proliferation and angiogenesis in mammary glands, tumors,
fat diets. (A) Proliferation: fold increases in proliferation in normal mamma
tumor epithelium from mice on a high fat diet (HFD) versus low fat diet (L
as measured by proliferating cell nuclear antigen (PCNA); *P <0.05. Note, th
At 10 weeks, mice fed HFD exhibited increased cellular proliferation in both
deoxyuridine (BrdU) incorporation; *P <0.05. Early developing tumors on HF
BrdU incorporation; *P <0.05. (B) Angiogenesis: blood vessel density was m
by CD31-positive vessels near normal mammary epithelium at 3, 4, and 10
10 weeks, CD31-stained vessels were significantly increased adjacent to no
and microscopic tumors (tumors versus hyperplasia; ***P = 0.02) in HFD-fed
greater in HFD-E tumors (#P = 0.01) compared to LFD tumors. (C) Insets sho
(i) an LFD tumor. Scale bars = 50 mm.highest proliferation seen at 10 weeks in normal mam-
mary structures and hyperplastic lesions. Proliferation
was also significantly greater in HFD-E tumors, but was
less than that seen after 10 weeks on HFD.
Since tissues and tumors require adequate vascularization
to sustain proliferation, we also measured angiogenesis, as
determined by blood vessel density (Figure 2B, C). At 3 and
4 weeks on diet, blood vessel density was low and inde-
pendent of diet. At 10 weeks on diet, HFD-fed mice exhib-
ited significantly increased blood vessel density around
normal mammary gland structures and foci of atypical
hyperplasia compared with LFD-fed mice. Notably, blood
vessel density was highest around microscopic, non-
palpable tumors in HFD-fed mice. HFD-E tumors also ex-
hibited increased blood vessel density.
To gain further insight into the enhanced proliferative
characteristics observed on HFD, we analyzed RNA ex-
pression by qRT-PCR using PCR arrays targeted to
Growth Factors (Table 2). At 3 weeks, Fgf18 and Il4 were
upregulated, and at 4 weeks, brain derived neurotrophic
factor (Bdnf ) and leukemia inhibitory factor (Lif ) were
upregulated, whereas Lefty2 was downregulated. Inter-
estingly, at 4 weeks on HFD, only RANKL was robustly
upregulated 17-fold. RANKL is a P-regulated paracrine
growth factor in the mammary gland [28-30], and HFD-and tumor microenvironments in mice fed on high fat and low
ry epithelium at 4 and 10 weeks, hyperplastic foci at 10 weeks, and in
FD). At 4 weeks, mice fed HFD exhibited increased cellular proliferation
e 4-week data are a re-analysis of data published in Olson et al. (2008).
normal epithelium and hyperplastic foci, as measured by 5-bromo-2’-
D (HFD-E) also exhibited increased cellular proliferation, as measured
easured, as described in Materials and Methods, by the area occupied
weeks, and in tumor epithelium from mice on HFD versus LFD. At
rmal mammary gland structures (*P = 0.01), hyperplastic foci (**P = 0.04)
compared to low fat diet (LFD)-fed mice. CD31 staining was also
w increased CD31 staining of (ii) an HFD-E tumor compared with
Table 2 Targeted Q-PCR analysis of mammary glands
after 3, 4, or 10 weeks and mammary tumors on HFD
versus LFD
Growth factor genes Fold change HFD versus LFD







Fgf18 Fibroblast growth factor 18 2.0 - - -
Il4 Interleukin 4 2.0 - - -
Bdnf Brain derived neurotrophic
factor
- 2.4 - -
Lefty2 Left-right determination
factor 2
- −2.5 - -
Lif Leukemia inhibitory factor - 2.8 - -
RANKL Receptor activator of nuclear
factor kappa-B ligand
- 17 - -
Bmp2 Bone morphogenetic
protein 2
- - 2.0 -
Bmp3 Bone morphogenetic
protein 3
- - 2.4 -
Fgf10 Fibroblast growth factor 10 - - 2.0 -
Gdf10 Growth differentiation
factor 10
- - 1.9 -
Gdf5 Growth differentiation
factor 5
- - 2.2 -
Nodal Nodal - - 2.4 -
Pgf Placental growth factor - - 2.5 -
Tgfa Transforming growth
factor alpha
- - 1.9 -
Tgfb1 Transforming growth
factor, beta 1
- - 1.9 -
Vegfa Vascular endothelial
growth factor A
- - 2.1 -
Il1a Interleukin 1 alpha - - 3.0 -
Il1b Interleukin 1 beta - - 2.1 -
Il2 Interleukin 2 - - 3.0 -
Il7 Interleukin 7 - - 3.4 -
Cxcl12 Chemokine (C-X-C motif )
ligand 12
- - 1.8 -
Bmp7 Bone morphogenetic
protein 7
- - - 3.2
Inha Inhibin alpha - - - 2.2
Ntf3 Neurotrophin 3 - - - 53.4
Bmp10 Bone morphogenetic
protein 10
- - - −3.4
N = 3 high fat diet (HFD) mice, n = 3 low fat diet (LFD) mice, n = 3 HFD mice
with early developing tumors (HFD-E), n = 3 LFD mice with tumors. P ≤0.05 for
all genes listed.
Zhao et al. Breast Cancer Research 2013, 15:R100 Page 8 of 20
http://breast-cancer-research.com/content/15/5/R100induced RANKL upregulation could contribute to the in-
creased proliferation observed at 4 weeks on diet. There
was no specific overlap in mammary gland gene expres-
sion at 3 or 4 weeks on diet.
At 10 weeks on diet, a large number of growth factor
genes were upregulated in mammary glands of HFD-fedmice. The one with most obvious relevance to mammary
epithelial proliferation was TGFα [31], a ligand for the
EGF receptor (EGFR). Other upregulated genes included
several encoding TGFβ superfamily growth factors [32]
(that is, Bmp2, Bmp3, growth differentiation factor (Gdf )
5, Gdf10, Nodal, and Tgfb1), as well as genes encoding
IL-2, IL-7, FGF10, PGF, VEGF-A, Chemokine (C-X-C
motif ) ligand (CXCL) 12, IL-1α, and IL-1β. Interestingly,
there was no specific overlap with growth factors found
induced at 3 and 4 weeks on HFD.
Analysis of growth factor-related gene expression in the
HFD-E tumors in comparison to LFD tumors showed up-
regulation of bone morphogenic protein (Bmp) 7, and
inhibin α (Ihha), as well as a trend toward upregulation of
Fgf15 (P = 0.09). Neurotrophin 3 (Ntf3) was most robustly
upregulated (53-fold). Bmp10 was downregulated. It is
striking that the HFD-E tumors display a unique gene ex-
pression profile that shows no overlap with the genes
identified at 3, 4, and 10 weeks on diet.
Effect of diet on inflammatory processes
Leukocytes (that is, macrophages, eosinophils and mast
cells) play important roles in normal pubertal mammary
gland proliferation and development [9-11]. Since HFD
promoted mammary epithelial cell proliferation, we also
examined the effect of diet on leukocyte recruitment
(Figure 3). At 3 weeks, there was a significant HFD-
induced increase in recruitment of eosinophils to all
mammary structures (Figure 3A) and of mast cells to
large ducts (Figure 3B). At 4 weeks, this effect was no
longer seen; however, high levels of eosinophils were ob-
served around TEBs on both diets (Figure 3A). Macro-
phage recruitment to glandular structures was similar at
3 and 4 weeks, and was independent of diet (data not
shown). The majority of macrophages were of the M2
phenotype (that is, Arg1+) for both diets.
At 10 weeks on diet, HFD-fed mice had significantly
more macrophages recruited to all normal mammary
gland structures (Figure 3C). With both diets, the vast ma-
jority of recruited macrophages were M2-polarized. The
greater number of macrophages recruited at 10 weeks on
HFD did not appear to be due to an interaction with
DMBA because the same fold increases in macrophages
were detected at 10 weeks on HFD diet without DMBA
treatment (data not shown). There were exceedingly low
numbers of eosinophils and mast cells on either diet (data
not shown). There were significantly more M2 macro-
phages present within HFD-E tumors and within their
tumor stroma (Figure 3D). There were no significant
differences in the numbers of eosinophils and mast cells
associated with HFD-E or LFD tumors (data not shown).
To gain a better understanding of how HFD increased
leukocyte recruitment, we compared the expression of
inflammation-related genes in LFD and HFD mammary
Figure 3 Inflammatory cell recruitment in mammary gland, tumors, and tumor microenvironments in high fat diet- and low fat diet-
fed mice. (A and B) BALB/c mice were started on diets at 3 weeks of age and terminated after 3 or 4 weeks for analysis of eosinophil (A) and
mast cell (B) recruitment to mammary gland epithelial structures, as described in the Materials and Methods. At 3 weeks on diet, eosinophil
recruitment (A) for all mammary structures and mast cell recruitment (B) for large ducts was significantly increased in high fat diet (HFD)
compared to low fat diet (LFD)-fed mice. *P = 0.0001; **P = 0.03. (C, D, E, and F) Sections from mice terminated at 3 weeks on diet (C), 4 weeks
on diet (D), 10 weeks on diet (E) and from HFD-E and LFD tumors (F) were double immunofluorescently stained with anti-F4/80 and anti-Arg1
antibodies, as described in Materials and Methods, and then analyzed for macrophage recruitment. At 10 weeks, total macrophage (F4/80) and
M2 macrophage (Arg1 + F4/80) recruitment (E) was increased adjacent to small ducts (*P = 0.01) and large ducts (**P = 0.05) in mammary glands
of HFD-fed mice. The increase in F4/80 and Arg1 + F4/80 staining in HFD versus LFD hyperplasia was not significant (P = 0.16). Tumor-associated
macrophages (F) were quantified based on their location at the tumor edge, within the tumor (intra-tumor), in the tumor stroma (stroma), and
combined for total tumor-associated macrophages. *P = 0.05 that there were more F4/80 and Arg1 + F4/80 labeled macrophages within HFD-E tu-
mors. #P = 0.01 that there were more Arg1 + F4/80 macrophages (total) in HFD-E tumors and within HFD-E stroma.
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and Receptors PCR array (Table 3). There was no overlap
in inflammation-related mRNA expressed at 3, 4, and
10 weeks on diet. Genes encoding CCL24 (eotaxin-2),
CCL3 (MIP-1α), IL-4, and IL5Rα were transiently inducedat 3 weeks. RANKL was the only upregulated inflamma-
tory gene observed at 4 weeks.
At the 3- and 4-week diet time points, mice also had
one inguinal mammary gland surgically cleared of en-
dogenous mammary epithelium (cleared fat pad), whereas
Table 3 Targeted qPCR analysis of mammary glands after
3, 4, or 10 weeks on HFD versus LFD
Inflammation PCR array Fold change HFD
versus LFD






Ccl24 Chemokine (C-C motif ) ligand 24 2.7 - -
Ccl3 Chemokine (C-C motif ) ligand 3 2.3 - -
Il4 Interleukin 4 2.2 - -
Il5ra Interleukin 5 receptor, alpha 3.0 - -
RANKL Receptor activator of nuclear factor
kappa-B ligand
- 17 -
Ccl1 Chemokine (C-C motif ) ligand 1 - - 4.5
Ccl17 Chemokine (C-C motif ) ligand 17 - - 3.2
Ccl19 Chemokine (C-C motif ) ligand 19 - - 7.5
Ccl20 Chemokine (C-C motif ) ligand 20 - - 5.2
Ccl22 Chemokine (C-C motif ) ligand 22 - - 7.6
Il1b Interleukin 1 beta - - 2.1
Il2rb Interleukin 2 receptor, beta chain - - 2.7
Cxcr2 Chemokine (C-X-C motif ) receptor 2 - - 4.3
Lta Lymphotoxin A - - 3.2
Xcr1 Chemokine (C motif ) receptor 1 - - 2.5
N = 3 high fat diet (HFD) mice, n = 3 low fat diet (LFD) mice; n = 3 mice with
early developing tumors while on HFD (HFD-E), n = 3 LFD mice with tumors.
P ≤0.05 for all genes listed.
Table 5 Targeted qPCR analysis comparing HFD-E tumors
with LFD tumors
Breast cancer genes HFD-E versus LFD
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was done to identify effects that can be mediated in the fat
pad independently of epithelial cells. Analysis of mam-
mary gland inflammatory gene expression showed that
upregulated genes only overlapped with that in intact
glands for Il5ra at 3 weeks (Table 4). At 4 weeks, however,
the cleared fat pads showed robust upregulation of Il1f6
(Il36α) (6.5-fold) and Il1f8 (Il36β) (4.9-fold). These genes
were not upregulated in intact glands.Table 4 Targeted qPCR analysis of intact mammary
glands and epithelium-devoid fat pads on HFD versus
LFD
Fold change HFD versus LFD
Gene 3 wks intact 3 wks cleared 4 wks intact 4 wks cleared
Ccl24 2.7 - - -
RANKL - - 17.0 -
Ccl3 2.3 - - -
Il4 2.2 - - -
Il5ra 3.0 3.3 - -
Il1f6 - - - 6.5
Il1f8 - - - 4.9
N = 3 high fat diet (HFD) mice, n = 3 low fat diet (LFD) mice. P ≤0.05 for all
genes listed.The Inflammatory Cytokines and Receptors PCR array
identified 10 genes that were upregulated by HFD at
10 weeks on diet (Table 3). The upregulated genes were
Il1b, Il2rb, lymphotoxin α (Lta), and a number encoding
immune chemokines and chemokine receptors: chemo-
kine (C-C motif ) ligand (Ccl) 1, Ccl17, Ccl19, Ccl20,
Ccl22, chemokine (C-motif ) receptor 1 (Xcr1), and che-
mokine (C-X-C motif ) receptor (Cxcr) 2. Similar to the
Growth Factor gene analysis, there was no overlap be-
tween the genes found to be modulated at 3, 4, and
10 weeks on diet.Tumor characteristics
To determine the properties of HFD-E tumors that
could explain their reduced latency and their enhanced
proliferative characteristics, we also analyzed RNA ex-
pression by qRT-PCR using Breast Cancer, and Cancer
Pathway Finder PCR arrays. This analysis (Table 5)
showed upregulation of cyclin D2 (Ccdn2), insulin-like
growth factor 1 receptor (Ifg1r), telomerase reverse tran-
scriptase (Tert), Slit2, and β-catenin (Ctnnb1) expression,
whereas keratin 8 (Krt8) and keratin 18 (Krt18) were
expressed at lower levels. Discordant with the pro-
tumorigenic properties of many genes upregulated in
HFD-E tumors, several upregulated genes are known
tumor suppressors (Brca2 [33], Slit2 [34], Trp53 [35],
Apaf1 [36], and Brca1 [33]). Nonetheless, it is striking
that the HFD-E tumors displayed a unique gene expres-
sion profile in comparison to LFD tumors.tumor
Symbol Description Fold change
Brca2 Breast cancer 2 1.8
Ccnd2 Cyclin D2 3.5
Igf1r Insulin-like growth factor I receptor 3.5
Slit2 Slit homolog 2 (Drosophila) 2.9
Trp53 Transformation related protein 53 1.6
Krt18 Keratin 18 −3.8
Krt8 Keratin 8 −4.7
Cancer pathway finder genes HFD-E versus LFD
tumor
Apaf1 Apoptotic peptidase activating factor 1 1.8
Brca1 Breast cancer 1 1.8
Ctnnb1 Catenin (cadherin associated protein), beta 1 1.8
Tert Telomerase reverse transcriptase 1.9
N = 3 mice with early developing tumors while on high fat diet (HFD-E), n = 3
low fat diet (LFD) mice with tumors. P ≤0.05 for all genes listed.
Table 6 Top canonical pathways of 3, 4, and 10 weeks on diet and tumor sample groups
qPCR
dataset




Communication between Innate and Adaptive Immune Cells 9.11E-03 2/109 CCL3L1/CCL3L3, IL4
Granulocyte Adhesion and Diapedesisa 9.33E-03a 2/175a CCL3L1/CCL3L3, CCL24
Agranulocyte Adhesion and Diapedesisa 9.33E-03a 2/186a CCL3L1/CCL3L3, CCL24
4 weeks
Human Embryonic Stem Cell Pluripotency 1.44E-04 3/156 BDNF, FZD5, LEFTY2
Mouse Embryonic Stem Cell Pluripotency 4.07E-03 2/99 LIF, FZD5
Role of NANOG in Mammalian Embryonic Stem Cell
Pluripotencya
4.07E-03a 2/114a LIF, FZD5
Role of Osteoblasts, Osteoclasts and Chondrocytes in
Rheumatoid Arthritis
1.20E-02 2/238 TNFSF11, FZD5
Role of Macrophages, Fibroblasts and Endothelial Cells in
Rheumatoid Arthritisa
1.83E-02a 2/332a TNFSF11, FZD5
10 weeks
Granulocyte Adhesion and Diapedesisa 5.66E-09a 8/166a IL1A, CXCR2, CCL17, CCL20, IL1B, CCL22,
CCL19, CCL1
Agranulocyte Adhesion and Diapedesisa 5.66E-09a 8/176a IL1A, CXCR2, CCL17, CCL20, IL1B, CCL22,
CCL19, CCL1
Hepatic Fibrosis / Hepatic Stellate Cell Activation 1.55E-06 6/140 VEGFA, IL1A, TGFB1, TGFA, IL1B, PGF
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 3.24E-06 5/86 IL1A, IL2, TGFB1, LTA, IL1B
Role of Macrophages, Fibroblasts and Endothelial Cells in
Rheumatoid Arthritisa
3.32E-06a 7/311a VEGFA, IL1A, TGFB1, LTA, IL1B, IL7, PGF
Tumor
Molecular Mechanisms of Cancer 7.10E-07 7/378 TP53, CCND2, APAF1, BMP7, BRCA1,
CTNNB1, BMP10
p53 Signaling 7.10E-07 5/96 TP53, CCND2, APAF1, BRCA1, CTNNB1
Basal Cell Carcinoma Signaling 1.27E-05 4/73 TP53, BMP7, CTNNB1, BMP10
GADD45 Signaling 1.43E-05 3/22 TP53, CCND2, BRCA1
Role of NANOG in Mammalian Embryonic Stem Cell
Pluripotencya
4.54E-05a 4/114a TP53, BMP7, CTNNB1, BMP10
aPathways that are common between groups, with 10 weeks on diet, and tumor groups having an increased number of pathway molecules from 3 and 4 weeks
on diet. B-H, Benjamini-Hochberg.
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In ontology analyses (Table 6), few canonical pathways
were altered at 3 weeks and 4 weeks, and among those
pathways that met statistical significance criteria, few genes
per pathway were significantly altered (see Additional files
7, 8). By 10 weeks, a much broader range of genes were
altered and several statistically significant pathways
were identified, including Granulocyte and Agranulo-
cyte Adhesion and Diapedesis (P = 5.66 × 10-9), Hepatic
Fibrosis/Hepatic Stellate Cell Activation (P = 1.55 × 10-6),
Altered T Cell and B Cell Signaling in Rheumatoid Arth-
ritis (P = 3.24 × 10-6), and Role of Macrophages, Fibroblast
and Endothelial Cells in Rheumatoid Arthritis (P = 3.32 ×
10-6) (see Additional file 9). The ontology analyses also
identified several statistically significant pathways altered
in the HFD-E tumors. These include Molecular Mecha-
nisms of Cancer (P = 7.1 × 10-7), p53 Signaling (P = 7.1 ×
10-7), Basal Cell Carcinoma Signaling (P = 1.27 × 10-5),
GADD45 Signaling (P = 1.43 × 10-5), and Role of NANOG
in Mammalian Embryonic Cell Pluripotency (P = 4.54 ×
10-5) (see Additional file 10).Dietary effects on metabolic parameters, hormone levels
and systemic factors
As shown in Additional file 3, there were no major dif-
ferences in non-fasting blood insulin or blood glucose
levels at 10 weeks on LFD or HFD, or in HFD-E and
LFD tumor-bearing mice. Mice fed LFD and HFD had
glucose levels in the normal non-fasting range for
BALB/c mice (<319 mg/dL) (see Additional file 3: Figure
S2A,C) [37]. Non-fasting serum insulin levels were simi-
lar at 10 weeks between LFD and HFD, with some values
in the hyperinsulinemic range (normal non-fasting insu-
lin = 0.77 ng/mL) (see Additional file 3: Figure S2B) [37].
Insulin levels in HFD-E and LFD tumor-bearing mice
varied widely and generally were in the hyperinsulinemic
range (see Additional file 3: Figure S2D). The high insu-
lin values were most likely indicative of some degree of
insulin resistance. There were no differences in E or P
levels at 4 or 10 weeks on HFD or LFD, or in tumor
bearing mice (data not shown).
Plasma levels of additional growth and inflammatory
factors were measured by Ab arrays to investigate
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At 4 weeks on HFD, the levels of OPG and IGF-1 were sig-
nificantly elevated (1.3-fold, P = 0.04 and 1.3-fold, P = 0.005,
respectively); this increase was transient and not seen
at later time points, or in tumor-bearing mice. At 10 weeks
on HFD, the only significantly modulated systemic protein
was prolactin, of which there was decreased plasma ex-
pression (0.68-fold, P = 0.03). However, there was a trend
toward increased IL-1α levels (7.8-fold, P = 0.066). In
HFD-E tumors, HGF was significantly increased (2.1-fold,
P = 0.046). We compared mammary glands for mRNA ex-
pression of the factors detected in the plasma samples.
The possible increase in systemic IL-1α parallels the sig-
nificant increase in mammary gland Il1a RNA expression
observed at 10 weeks on HFD (Table 3). Notably, mRNA
encoding OPG, IGF-1, HGF, and prolactin were not de-
tected at any time point in mammary gland or tumors,
suggesting alternative systemic sources for their presence
in plasma.Discussion
In this study we have identified the effects of HFD
started during puberty, to reduce the latency of DMBA-
induced mammary cancers. Most notably, tumors that
developed early (HFD-E) had important characteristics
that differed from those of LFD tumors that developed
significantly later. We identified the likely major contrib-
utors to HFD-induced decreased latency as local and
systemically increased growth factor expression, and
promotion of inflammatory and angiogenic processes.
This occurred without causing significant body weight
gain or obesity, and the metabolic effects of HFD on
blood glucose and insulin levels were modest. It is par-
ticularly noteworthy that, although DMBA mutagenesis
is virtually random in its targeting of genes in tumori-
genesis, the tumors arising with short latency on HFD
showed a unique gene expression profile, highlighting
the potent overarching influence of HFD.Table 7 Effect of diets on plasma levels of growth and
inflammatory factors
4 wks on diet 10 wks on diet Tumors
HFD versus LFD HFD versus LFD HFD-E versus LFD
Serum factor Fold change Fold change Fold change
HGF - - 2.1
OPG 1.3 - -
IGF-1 1.3 - -
prolactin - 0.68 -
N = 4 mice on high fat diet (HFD) for 4 wks, n = 4 mice on low fat diet (LFD)
for 4 wks; n = 4 mice on HFD for 10 wks, n = 4 mice on LFD for 10 wks; n = 6
HFD mice with early developing tumors (HFD-E), n = 6 LFD mice with tumors.
P ≤0.05 for all genes listed.Proliferation
We previously reported that pubertal BALB/c mice fed
HFD for 4 weeks showed increased mammary epithelial
cell proliferation [18]. Herein, we observed that HFD in-
duced elevated mammary gland expression of several
growth factor genes as early as 3 and 4 weeks on diet. In
particular, RANKL was robustly induced at 4 weeks.
RANKL is a P-induced paracrine factor that has known
mitogenic activity in the mammary gland [38-40].
Plasma levels of OPG, a decoy receptor and RANKL an-
tagonist [41], were also elevated at this time, and this
may reflect a physiologic response to excess mammary
RANKL levels. Additionally, plasma levels of IGF-1 were
elevated at this time. Systemic IGF-1 and mammary
gland expression of RANKL are plausible early sources
of enhanced proliferation prior to the appearance of tu-
mors in HFD-fed BALB/c mice [28-30,42,43]. IGF-1 is
an essential growth factor for TEB formation [42] that
has been implicated in breast cancer progression [43].
By 10 weeks on HFD, a time point prior to the appear-
ance of palpable tumors, mammary glands showed in-
creased numbers of abnormal mammary epithelial
lesions, and enhanced cellular proliferation. Increased
levels of the RNA encoding growth factors associated
with mammary epithelial cell proliferation and develop-
ment were detected. Perhaps most provocative among
these was the gene encoding TGFα, an EGFR ligand that
has been associated with precocious alveologenesis,
delayed involution, and mammary tumorigenesis [21].
Interestingly, it was recently reported that paracrine
EGFR signaling between tumor-associated macrophages
and murine breast cancer cells can promote a cancer
stem cell-like phenotype [44]. Also provocative was the
increased expression of a number of genes in the TGF-β
superfamily (Bmp2 and 3, Gdf5 and 10, Nodal, and Tgfb1)
in HFD-fed mice. Signaling by TGF-β1 family members
mediate embryonic development, tissue homeostasis and
regeneration, immune responses, tumor suppression, and
metastasis, as well as govern the behavior of many stem
cell populations [45-48]. TGF-β1 has an established role
in mammary gland ductal development [49-51]. The
Nodal signaling pathway is activated by Cripto-1, which
encodes a growth factor with a role in mammary gland de-
velopment that is capable of inducing ductal hyperplasia
[52]. Lefty2, which was downregulated at 4 weeks, func-
tions as an antagonist of the Nodal pathway [53], and this
earlier downregulation may set the stage for activation of
Nodal signaling at 10 weeks. Specific roles for Bmp3 and
Gdf10 in the mammary gland have not been reported.
Increased Tert expression is also associated with the
immortalization of cells, and as such, it antagonizes apop-
tosis [54]. This may also contribute to a proliferative
phenotype. Indeed, 95% of human cancers show increased
Tert activity [55]. Upregulation of genes encoding IL-2
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tumors [56,57]; these were also upregulated in mammary
glands of 10-week HFD-fed mice.
Analysis of HFD-E tumor characteristics showed in-
creased cellular proliferation that was associated with
upregulation of genes that promote cellular proliferation
such as Bmp7, Ccdn2, Inha, and Igf1r. BMPs are recog-
nized as key regulators during the control of cell fate
and cancer development [58], and BMP signaling can
downregulate levels of mitotic checkpoint components
in human breast cancer cells [59]. Bmp7 has also been
implicated in increasing the metastatic potential of 4 T1
mouse mammary tumor cells [60]. There was also a
trend toward upregulation of Fgf15 (P = 0.09). FGFs and
their receptors control a wide range of biological func-
tions operative in cancer including cellular proliferation
[61]. On the other hand, Bmp10, which has been shown
to decrease aggressiveness of breast cancer cells [62],
was downregulated in HFD-E tumors. Thus, decreased
Bmp10 expression is consistent with greater cellular pro-
liferation of HFD-E tumors. Expression of IGF-1R is
known to be increased in human breast cancers and as-
sociated with increased cellular proliferation [63-66]. In-
hibins are growth factors that are also involved in cell
proliferation and differentiation, and inhibin α is expressed
in normal mammary tissues and in human breast cancers;
however, its specific role in tumors is not well understood
[67]. The increased expression of Ccdn2 is discordant with
enhanced tumorigenesis of HFD-E tumors, as loss of cyclin
D2 expression is frequent in breast cancers [68]. However,
transgenic overexpression of cyclin D2 does block lobuloal-
veolar development [69] and, perhaps, Ccdn2 overexpres-
sion in our system could be viewed as suppressing
differentiation.
Several genes that are activated in response to DNA
damage (Brca1, Brca2, and Trp53) were upregulated in
HFD-E tumors. Trp53 is a downstream target of Brca1
[70], and Apaf1, an important mediator of apoptosis that
is a downstream target of Trp53, is also upregulated
[71]. Thus, the upregulation of these genes appears to
constitute the upregulation of a pathway associated with
DNA damage, perhaps resulting from exposure to the
mutagenic carcinogen DMBA, rather than the coinci-
dent overexpression of several mutated tumor suppres-
sor genes. It is plausible that Trp53 upregulation of
Apaf1 is related to removal of damaged cells by apop-
tosis [71]. While DMBA treatment was dissociated in
time from the occurrence of tumors, DMBA is known to
induce aneuploidy and unstable karyotypes that might sus-
tain DNA damage long after exposure [72]. Additionally,
expression of Krt8 and 18, associated with more differenti-
ated mammary luminal cells [73,74], was significantly de-
creased, suggesting a more aggressive phenotype of HFD-E
tumors. In regard to increased Ctnnb1 expression, theWnt/β catenin pathway is involved in normal mam-
mary gland proliferation and development, and associ-
ated with poor prognosis in breast cancer [75]. Elevated
Ctnnb1 (β-catenin) expression may activate this pathway.
HGF was elevated in the plasma of HFD-E tumor-
bearing mice, and may play a role in driving HFD-E
tumor growth. HGF regulates multiple cellular processes
that stimulate cell proliferation, invasion, and angiogen-
esis, both in the normal mammary gland [76] and in
breast cancer [77]. HGF is generally produced locally
within the mammary gland/mammary cancer and acts in
a paracrine manner. However, no HFD-induced increase
in mammary gland or tumor expression of HGF was ob-
served in the present study. Recently, HGF serum levels
were reported to be significantly elevated with increasing
tumor stage in breast cancer patients, raising the possi-
bility of alternate sites of HGF production [78].
The integrated overview of the various aforementioned
genes that is provided by pathway analysis tends to sup-
port the notion that genotoxic stress has activated p53
and Gadd45 signaling, two pathways associated with
DNA damage [79,80]. The altered expression of Trp53,
Ccnd2, Apaf1, Brca1, and Ctnnb1 identified the p53 sig-
naling and GADD45 signaling pathways to high signifi-
cance. Provocatively, altered expression of a partially
overlapping set of genes, Trp53, Bmp7, Ctnnb1, and
Bmp10, identified the Basal Cell Carcinoma signaling
and Role of NANOG in Mammalian Stem Cell Pluripo-
tency pathways. This suggests similarity between the
HFD-E tumors and breast tumors displaying stem and/
or progenitor cell characteristics, such as basal-like
breast cancer [81]. The downregulation of luminal epi-
thelial makers, Krt8 and 18, in HFD-E tumors is also
consistent with this. Although several of the HFD-E tu-
mors were ER-positive, basal-like breast cancers can ex-
press ERα [82]. Further, epidemiological studies have
associated basal-like breast cancer with increased ab-
dominal adiposity [83]; although HFD-E tumor-bearing
animals were not obese, obesity was associated with
HFD.
Angiogenesis
It is noteworthy that a number of genes associated with
angiogenesis (Gdf5, Nodal, Pgf, Vegfa, and Cxcl12) were
upregulated by HFD at 10 weeks, concomitant with the
observation of increased vascularity in the mammary
glands of HFD-fed mice. Nodal expression is signifi-
cantly elevated in malignant human breast cancers ver-
sus benign breast disease [84] and has been associated
with vasculogenic mimicry, defined as functional plasti-
city of aggressive cancer cells forming de novo vascular
networks [85]. GDF5 has also been shown to have angio-
genic properties [86]. PGF and VEGF-A, angiogenic pro-
teins of the VEGF family, are upregulated mainly in
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sociated with poor prognosis [87]. CXCL12, produced by
stromal fibroblasts within invasive breast cancers, pro-
motes angiogenesis [88] and has additionally been asso-
ciated with increased macrophage density in tumors
[89]. Coincident with the induction of the above men-
tioned genes associated with angiogenesis, analysis of
plasma at this time revealed decreased prolactin levels.
Prolactin is reported to have anti-angiogenic effects [90]
and its reduced expression may promote angiogenesis.
HFD-E tumors also exhibited increased blood vessel
density and genes associated with angiogenesis, such as
Ntf3, Bmp10, and Slit2, were also differentially regulated
in these tumors. In fact, Ntf3 was the most highly upreg-
ulated growth factor gene (53-fold). Neurotrophins and
the neurotrophin receptor p75 are expressed in human
breast cancers and are implicated in promoting angiogen-
esis, tumor growth, invasion, and resistance to apoptosis
[91]. Interestingly, in mice fed 60% HFD, neurotrophin ex-
pression is increased in the brain, suggesting its upregula-
tion here in HFD-E tumors may also be diet-induced [92].
Further, we found that Bdnf, another member of the neu-
rotrophin family of growth factor genes [93], was robustly
induced at 4 weeks on HFD, perhaps suggesting an associ-
ation between this family of growth factors and HFD.
Inflammatory processes
The induction of Ccl24 (eotaxin-2) and Ccl3 (MIP-1α)
RNAs at 3 weeks was concomitant with influx of eosino-
phils into the mammary peri-epithelial compartment.
Both CCL24 [94] and CCL3 [95] are potent chemoat-
tractants for eosinophils. Il5ra RNA is also elevated at
this time; IL-5 is a differentiation factor for eosinophil
progenitors [96]. Consistent with chemotaxis of eosino-
phils to adipose tissue, upregulation of Il4 RNA has also
been observed [97]. Ccl24, Ccl3, and Il4 mRNAs all had
high correlation with the level of eosinophils at 3 weeks
on diet (Ccl24: r = 0.865 to 0.886; Ccl3: r = 0.667 to
0.812; Il4: r = 0.714 to 0.943 (depending upon mammary
structural element); see Additional file 11). The induc-
tion of Il4 RNA has potentially important implications
for the function of macrophages in the mammary gland,
as eosinophil-derived IL-4 is essential for the mainten-
ance of alternatively activated (that is, M2) macro-
phages in adipose tissue [97]. This is consistent with
the high numbers of Arg1+ macrophages observed in
the peri-epithelial stroma of the normal gland at 3 and
4 weeks on diet, and in the vicinity of early lesions and
within tumors in DMBA/HFD-treated mice. While
pathway analysis did not identify any canonical path-
ways to a high level of significance, chemotaxis of
eosinophils was identified as a highly significant func-
tion (P = 6.4 × 10-5) (see Additional file 7), and eosi-
nophil levels correlated well with RNAs for all of theaforementioned chemokines and cytokine (see Additional
file 11). Another inflammatory growth factor RNA in-
creased in mice at 4 weeks was that encoding RANKL,
a potent activator of NF-κB [98]. Thus, RANKL may
play a role in the upregulation of pro-inflammatory fac-
tors at this time. In parallel to the analysis of whole in-
tact mammary gland at 3 and 4 weeks of diet, a similar
analysis of epithelium-devoid fat pads contralateral to
the intact mammary glands was carried out. At 3 weeks,
this revealed that Il5ra was similarly induced by HFD in
both cleared fat pads and intact glands, suggesting that
it is, in fact, associated with the stroma. At 4 weeks,
this analysis also revealed HFD induction of the genes
encoding IL-1f6 (IL-36α) and IL-1f8 (IL-36β), IL-1 fam-
ily cytokines known to be expressed in adipocytes as
inflammatory mediators [99]. This induction is not ob-
served in intact glands. It may be that the mammary
epithelium suppresses this induction in intact glands,
or, alternatively, that the stromal induction of these cy-
tokines is obscured in the intact gland by dilution or
because the same cytokines are downregulated in the
epithelium, while being upregulated in the stroma. This
highlights the mammary stroma as an epithelium-
independent source of inflammatory factors that can
mediate the effects of HFD.
At 10 weeks on diet, the RNA encoding a number of
cytokines and chemokines associated with immune func-
tion were modulated by HFD, and these may have pro-
found implications for the status of the immune system
at this point in time. Most interesting are the genes en-
coding the chemokines CCL1, CCL17, and CCL22, as
well as the cytokine TGF-β1, which are all associated
with the recruitment and function of immunosuppres-
sive Treg cells [100-102]. There is also one report of
CCL20 recruiting Treg cells in an induced colorectal
cancer model [103]. Further, these factors are all prod-
ucts of M2 macrophages, recruitment of which was in-
duced by HFD at 10 weeks of diet. In fact, TGF-β1
additionally can function in the generation of immuno-
suppressive M2 macrophages [104], perhaps, in part,
through the suppression of M1 macrophage activity
[105]. Upregulation of Ccl19, Ccl20 and chemokine (C-X-
C motif ) receptor (Cxcr) 2 has also been associated with
breast tumor growth and invasion [106-108], Cxcr2 par-
ticularly with angiogenic processes [108]. Systemic levels
of prolactin were also reduced at 10 weeks on HFD. As
prolactin can suppress the function of suppressor T cells
[109], a decrease in its expression would be expected to
enhance Treg activity. Indeed, increased numbers of Treg
cells have been associated with increased DMBA-induced
mammary carcinogenesis in mice [110], suggesting the
importance of Treg-associated chemokines in this experi-
mental system. Characterization of the influence of dietary
fat upon T cell populations awaits future studies.
Figure 4 Increase in significant genes identified by targeted
pathway PCR arrays between 4 and 10 weeks on diet. RNA
isolated from week 3, 4, and 10 diet groups were analyzed using
Growth Factors and Inflammatory Cytokines and Receptors PCR
arrays (SABiosciences). The week-3 sample group identified six
significant genes, the week-4 sample group identified five significant
genes, and the week-10 diet group identified twenty-five
significant genes.
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LFD at week 10 identified Granulocyte and Agranulocyte
Adhesion and Diapedesis (identified by Il1a, Cxcr2,
Ccl17, Ccl20, Il1b, Ccl22, Ccl19, and Ccl1), which is con-
sistent with leukocyte migration into the mammary
gland. Furthermore, immune cell trafficking (adhesion of
immune cells and leukocyte migration) was among func-
tions showing the highest significance at 10 weeks on
HFD (P = 1.64 × 10-13 and 2.03 × 10-13, respectively).
Pathway analysis also identified Altered T Cell and B
Cell Signaling in Rheumatoid Arthritis (identified by al-
tered expression of Il1a, Il2, Tgfb1, Lta, and Il1b) and
Role of Macrophages, Fibroblasts and Endothelial cells
in Rheumatoid Arthritis (identified by altered expression
of Vegfa, Il1a, Tgfb1, Lta, Il1b, Il7, and Pgf ) (see Add-
itional file 9), pathways that can lead to macrophage-
mediated pathology [111] and abnormal angiogenesis
[112]. The identification of the Hepatic Fibrosis/Hepatic
Stellate Cell Activation pathway (identified by Vegfa,
Il1a, Tgfb1, Tgfa, Il1b, and Pgf ) is interesting, as the
polarization of M2 macrophages is a critical component
of this pathology [113]. The levels of RNA encoding IL-
1b, a common factor in all of these pathways, correlated
well with the level of macrophages in the mammary
gland (r = 0.828 to 0.886 (depending upon mammary
structural element); see Additional file 11) suggesting
the plausibility that these pathways may operate, at least
in part, through macrophage recruitment. The genes in-
cluded on the PCR arrays were highly selected for genes
with established involvement in particular pathways
(that is, growth factors, inflammation). Thus, it is also
noteworthy to observe that the absolute number of sig-
nificant genes on each targeted pathway array increased
between week 4 and week 10 (Figure 4). The parallel in-
crease in expression of inflammation and growth factor
genes underscores that immune infiltrates can alter the
expression of cytokines with regulatory effects on mam-
mary epithelial proliferation.
The status of inflammatory processes also differed in
HFD-E tumors compared to LFD tumors. There was a sig-
nificant increase in intra-tumoral and stromal alternatively
activated M2 (Arg1+) macrophages. The M2 phenotype is
associated with tumor-associated macrophages that are
known to promote the growth of tumors through support
of angiogenic and tissue remodeling processes, as well as
immune suppression [114]. The increase in M2 macro-
phages is consistent with the enhanced vascularity of
HFD-E tumors in comparison to LFD tumors. While none
of the cytokines identified as expressed in HFD-E tumors
is known to generate M2 macrophages, Il4 is upregulated
at 3 weeks and Tgfb1 is upregulated at 10 weeks on HFD,
and these cytokines may be involved in the prior
polarization of M2 macrophages [104]. There is compel-
ling evidence at the molecular level that many cancers,including breast cancer, are linked to a dysregulated in-
flammatory response [115]. The present results that dem-
onstrate HFD-induced inflammatory processes involving
M2 macrophages are consistent with a role for these mac-
rophages and their secreted chemokines/cytokines in the
promotion of HFD-E tumors.
As for the role of HFD, there is evidence that it can in-
duce low-grade inflammation after feeding [116]. It has
been proposed that HFD induces post-prandial gut per-
meability allowing low levels of bacterial endotoxin from
the gut to enter the circulation and, thus, induce low-
grade inflammation [116,117]. There is also evidence that
saturated fatty acids can directly modulate inflammatory
processes through toll-like receptor 4 (TLR4) [118]. Pal-
mitic acid, an abundant component of lard [119], has par-
ticularly been implicated in TLR2 [120,121] and TLR4
signaling [120-123]. This stimulation has been associated
with increased IL-1 signaling [120]. This is consistent with
our observation of increased levels of Il1a and Il1b gene
expression after 10 weeks on HFD.Systemic metabolic effects of HFD
The levels of metabolism-related factors such glucose,
insulin, leptin, and resistin were not significantly altered
by HFD. However, an inflammatory growth factor RNA
that increased in HFD mice at 4 weeks was that
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lipolysis and fat loss [124-126]. This places LIF as a
plausible mediator contributing to the lack of weight
gain in BALB/c mice placed on HFD. At 10 weeks on
HFD, plasma IL-1α levels were increased. Since HFD
also increased mammary gland IL-1α mRNA expression
at 10 weeks, increased plasma levels might reflect spill-
over from the mammary gland or other tissues affected
by HFD. Palmitic acid has been associated with in-
creased IL-1 signaling [120], and elevation of serum IL-
1α has been reported in HFD-induced obesity in mice
[127]. Tumors showed a trend toward increased Fgf15
expression. FGF15-specific signaling is thought to con-
trol metabolic homeostasis associated with HFD to re-
store glucose tolerance and insulin sensitivity [128].
Other studies of the effect of dietary fat on normal
mammary gland development and tumorigenesis have
been carried out in rodents [129-131]. However, they
differ significantly from the current studies with regard
to species studied (rat versus mouse), differences in fat
formulations (corn oil versus lard), caloric content
(isocaloric versus non-isocaloric), obesogenic versus
non-obesogenic outcomes, development of metabolic
syndrome, and age at diet initiation. More similar stud-
ies on the effect of HFD on tumor development with-
out the confounding effects of obesity have been
performed in other mouse mammary cancer models.
Results vary by tumor model and age at diet initiation.
In two studies of the effects of HFD initiated at 4 weeks
of age in mice overexpressing HER2/Neu in the mam-
mary gland [14,15], HFD promoted tumor develop-
ment by increasing tumor incidence, but without
increasing tumor cell proliferation; there was only a
small increase in body weight and no insulin resistance
or hyperinsulinemia. In another study, HER2/Neu
transgenic mice fed HFD starting in adulthood, at
10 weeks of age, showed no difference in tumor la-
tency, incidence, or metastasis [132]. In a tumor trans-
plant model, mice were started on HFD at 4 weeks of
age, and after 16 weeks on diet, 4 T1 mammary carcin-
oma cells were transplanted into their mammary
glands [133]. There were only slight increases in body
weight with HFD. However, tumor weight and number
of metastases were significantly increased by HFD.
Thus, based on the results of the present study and of
the previous studies of HFD initiated in pubertal mice
(4 weeks of age), there was a significant promotional
effect on tumor development with only a modest effect
on weight gain or metabolic parameters. This is in
contrast to the lack of a promotional effect of HFD
when initiated in adult, 10-week-old mice. The most
extensive study was carried out in the 4 T1 tumor
transplant model with diet started at 4 weeks of age [133].
Similar to our present results, that study revealed anassociation of HFD with increased macrophage infiltra-
tion, angiogenesis, and cellular proliferation, as well as in-
creased levels of a number of inflammatory factors.Conclusions
Taken together, our results demonstrate that exposure
to HFD in the peri-pubertal period, and the sensitivity
of the pubertal gland to HFD, initiate a sequence of in-
flammatory, angiogenic, and growth-promoting effects
starting as early as 3 weeks on diet, which can lead to
the promotion of mammary cancer development in
adulthood. Notably, the observed effects of HFD were
independent of significant weight gain. Importantly,
this indicates a potential risk from HFD for a broader
segment of the population than only those who become
obese. The observation of a distinct expression profile
associated with the HFD-dependent shorter latency of
DMBA tumors highlights the potent influence of HFD
in the context of a virtually randomly targeted carcino-
gen. It is also particularly noteworthy that, in our
DMBA model and other tumor models, there is signifi-
cant promotion of tumorigenesis under the potent in-
fluence of HFD. Future studies are needed to identify
the specific effects of exposure to HFD at puberty ver-
sus adulthood, as well as to identify the mechanistic basis
for dietary fat effects and potential interventions to pre-
vent the promotional consequences of HFD exposure.Additional files
Additional file 1: Table S1. Diet formulations.
Additional file 2: Figure S1. Comparison of weight gains on Diets I
and II. BALB/c mice were started on high fat diet (HFD) and low fat diet
(LFD) I or II at 3 weeks of age and continued until 45 weeks of age. There
were virtually identical weight gains on both diets. The dips in weight
between 6 and 9 weeks were due to the response to 7,12-dimethylbenz
(a)anthracene (DMBA) treatments.
Additional file 3: Figure S2. Comparison of the effects of Diets I and II
on non-fasting blood levels of glucose and insulin. BALB/c mice were
started on high fat diet (HFD) or low fat diet (LFD) I or II at 3 weeks of
age. Blood levels of (A,C) glucose and (B,D) insulin were measured at 10
weeks on diet (A,B) or in tumor-bearing mice (C,D). The bars represent
the mean ± standard error of the mean for samples from five animals per
diet at 10 weeks on diet, six early developing tumors on HFD (HFD-E),
and five LFD tumor-bearing mice. *P = 0.02 HFDII blood glucose level
higher than LFD II at 10 weeks on diet.
Additional file 4: Figure S3. Comparison of the effects of diets I (A)
and II (B) on time-course of tumor development. Tumor development
was monitored starting after the last 7,12-dimethylbenz(a)anthracene
(DMBA) treatment. Kaplan-Meier plots show no significant differences in
latency of tumors developing on (A) low fat diet (LFD) I versus LFD II or
(B) high fat diet (HFD) I versus HFD II. Development of tumors in LFD-fed
mice was observed only after 18 weeks post-DMBA treatment on either
diet I or II. Time = days post last DMBA treatment.
Additional file 5: Table S2. Tumor incidence.
Additional file 6: Figure S4. Diagram of experimental design.
Additional file 7: Table S3. Three weeks on diet qPCR Ingenuity
Pathway Analysis.
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Pathway Analysis.
Additional file 9: Table S5. Ten weeks on diet qPCR Ingenuity Pathway
Analysis.
Additional file 10: Table S6. Tumor qPCR Ingenuity Pathway Analysis.
Additional file 11: Figure S5. Correlations between cytokine mRNA
expression and leukocyte recruitment. Cycle threshold (Ct) values for the
indicated mRNA in individual animals were normalized to the average Ct
values for GusB, Hprt1, Hsp90ab1, Gapdh, and Actb mRNA in the same
animals, and plotted against the indicated leukocyte counts in the same
animals in association with the indicated individual structures.
Correlations (r) were calculated by Spearman’s method.
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